> Home
 
  > About
 
  > Portfolio
 
  > News
 
  > Documents for download
 
  > Investors
 
  > Press Room
 
  > Policies and Ethics
 
  > Contact
 
  > Links


Karolinska Development
AB (publ)
org. nr. 556707-5048
Registered office: Solna
© Karolinska Development 2008

 

 

Portfolio

All companies in the KD portfolio address an unmet medical need. A company is typically founded on an innovation with a strong IP position or skills that are difficult to replicate.

Portfolio companies are primarily selected on the merit of their projects and the feasibility of concluding a development program through to a suitable proof of principle (POP). Pharmaceutical as well as medical technology applications are pursued irrespective of therapeutic use provided the innovation addresses a distinct medical need.

Initially most of the companies have a cost effective virtual organization until POP. This is achieved by using experts from within the KD network who contribute to several companies on a part time basis as well as using CROs and CMOs. The operative support by KD starts immediately and recruitment of the management team is gradually intensified to meet a more complex environment as projects mature.

For employment opportunities in the portfolio companies please contact the companies directly.

 

 

 
 

Actar AB
Aprea AB
Athera Biotechnologies AB
Avaris AB
Axelar AB
BioArctic Neuroscience AB
BioChromix Pharma AB
Biocis Pharma Ltd.
Bioneris AB
BioResonator AB
Biosergen A/S
Calabar International AB
Clanotech AB
Cogmed Systems AB
Cytoguide
DermaGen AB
Dilafor AB
Eribis Pharmaceuticals AB
HBV Theranostica AB
IMED AB
Independent Pharmaceutica AB
InDex Pharmaceuticals AB
Inhalation Sciences Sweden AB
Lipopeptide AB
NeoDynamics AB
NephroGenex Inc.
NeuroTherapeutics AB
NovaSAID AB
Omnio Healer AB
Oncopeptides AB
Pergamum AB
PharmaSurgics AB
Promimic AB
ProNoxis AB
SoftCure Pharmaceuticals AB
Umecrine AB
Umecrine Cognition AB
Umecrine Mood AB
XSpray Microparticles AB